In This Section

G Proteins and G Protein Coupled Receptors in Cancer

Monday April 23, 2018

9:30 am - 12:00 pm Eastern Time (ET)

Room 16B


Chair :

Paul Insel
University of California, San Diego

J. Silvio Gutkind
University of California, San Diego

GPCRs, the largest family of cell surface signaling proteins and the targets for >30% of FDA-approved drugs, play key physiological and pathophysiological roles, in part through their activation of heterotrimeric G proteins. Recent analyses of human cancer genomes revealed an unanticipated high frequency of mutations in G proteins and GPCRs in many tumor types, including the discovery of mutant GPCRs and G proteins as driver oncogenes. GPCRs also regulate tumor-induced angiogenesis, cancer stem cell maintenance, metastasis, and immune evasion of cancer. Speakers in this symposium will describe efforts to translate such recent knowledge into new pharmacological interventions for cancer prevention and treatment.


Martine Smit - Vrije Universiteit Amsterdam

Viral Hijacking of GPCR Networks in Cancer

Joan Heller Brown - University of California, San Diego

G Protein Regulation of Glioblastoma Stem Cells

J. Silvio Gutkind - University of California, San Diego

The Human Onco-GPCRome: Opportunities for Cancer Prevention and Treatment

Joshua Allen - Oncoceutics, Inc

Clinical Activity Novel GPCR Targeting Agents in Cancer: An Industry Perspective

Mikel Garcia-Marcos - Boston University

A Novel BRET Biosensor for Gαq-GTP Reveals Unique Properties of Cancer-associated GNAQ Mutants

Alyssa Rodriguez - University of California, San Diego

HRH1: A Novel GPCR Drug Target in Pancreatic Cancer